Why the study?
Do antiplatelet drugs (aspirin and clopidogrel) reduce the risk of thrombosis formation in patients with known CHD?
Do antiplatelet drugs (aspirin and clopidogrel) reduce the risk of thrombosis formation in patients with known CHD?
This review summarizes the pharmacology and evidence base for using aspirin and clopidogrel to prevent thrombosis in patients with coronary heart disease.
Supports antiplatelet use in CHD; leaves open questions on optimal regimens for prospective trials.
It is established practice to administer antiplatelet drugs to patients with known CHD (Department of Health, 2000). This pharmacological prevention is based on the findings of a number of randomized controlled trials that have set out to establish a drug of choice and the dose required to reduce the risk of thrombosis formation. The following paper will review the role of platelets in maintaining haemostasis and in cardiovascular disease. It will then discuss how antiplatelet drugs can inhibit the function of platelets and so reduce the risk of thrombosis formation. The pharmacology of aspirin and clopidogrel will be reviewed and the evidence base presented for their use.
No takes yet. Share an insight, caveat, or question.
Helen Walthall (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: